SCHEMBL4666382

SCHEMBL4666382

CC(Cc1c[nH]c2ccccc12)C(N)=O

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.76
KDM4E B2RXH2 2/20 0.76
MAPT P10636 2/20 0.76
APAF1 O14727 1/20 0.76
RECQL P46063 1/20 0.76
L3MBTL1 Q9Y468 1/20 0.76
HTR2A P28223 2/20 0.65
ADRB1 P08588 1/20 0.65
HTR1A P08908 1/20 0.65
ADRA2A P08913 1/20 0.65
SLC6A2 P23975 1/20 0.65
HTR1D P28221 1/20 0.65
HTR1B P28222 1/20 0.65
HTR2C P28335 1/20 0.65
HTR1E P28566 1/20 0.65
SLC6A4 P31645 1/20 0.65
HTR7 P34969 1/20 0.65
HTR2B P41595 1/20 0.65
HTR6 P50406 1/20 0.65
SLC6A3 Q01959 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8266826 1.00 POLB (0.76) POLBKDM4EMAPTAPAF1RECQL
SCHEMBL9880194 0.86 POLB (1.00) POLBKDM4EMAPTAPAF1RECQL
SCHEMBL17326082 0.86 POLB (0.78) POLBKDM4EMAPTAPAF1RECQL
SCHEMBL5159730 0.86 POLB (1.00) POLBKDM4EMAPTAPAF1RECQL
SCHEMBL13971370 0.86 POLB (0.78) POLBKDM4EMAPTAPAF1RECQL
SCHEMBL9880193 0.86 POLB (1.00) POLBKDM4EMAPTAPAF1RECQL
SCHEMBL7602497 0.85 MAPT (0.59) POLBKDM4EMAPTAPAF1RECQL
SCHEMBL25766157 0.85 KDM4E (0.63) POLBKDM4EMAPTAPAF1RECQL
SCHEMBL19687957 0.85 KDM4E (0.67) POLBKDM4EMAPTAPAF1RECQL
SCHEMBL3158262 0.84 KDM4E (0.70) POLBKDM4EMAPTAPAF1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1518445-A Treatment of sexual dysfunction 沃纳-兰伯特公司 2004-08-04 CN claimed
WO-2023102507-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2023-06-08 WO disclosed
US-11564971-B2 Hyaluronic acid derivative having amino acid and steryl group introduced thereinto CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-01-31 US disclosed
US-20220160849-A1 CANCER VACCINE FORMULATION MIE UNIVERSITY (JP) 2022-05-26 US disclosed
EP-3919072-A1 CANCER VACCINE PREPARATION Mie University (JP) 2021-12-08 EP disclosed
US-20160193359-A1 NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF SEATTLE GENETICS, INC. (US) 2016-07-07 US disclosed
US-20150231268-A1 HYALURONIC ACID DERIVATIVE HAVING AMINO ACID AND STERYL GROUP INTRODUCED THEREINTO CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-08-20 US disclosed
US-20150231268-A1 HYALURONIC ACID DERIVATIVE HAVING AMINO ACID AND STERYL GROUP INTRODUCED THEREINTO CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-08-20 US disclosed
US-8992932-B2 Binder-drug conjugates (ADCs) and use thereof SEATTLE GENETICS, INC. (US) 2015-03-31 US disclosed
US-20130095123-A1 New binder-drug conjugates (ADCs) and use thereof Bayer Pharma AG (DE) 2013-04-18 US disclosed
US-7365090-B2 Substituted phenylindoles for the treatment of HIV IDENIX PHARMACEUTICALS, INC. (US) 2008-04-29 US disclosed
EP-1912970-A2 ACYLTRYPTOPHANOLS FOR FERTILITY CONTROL Bayer Schering Pharma Aktiengesellschaft (DE) 2008-04-23 EP disclosed
WO-2007017289-A2 ACYLTRYPTOPHANOLS FOR FERTILITY CONTROL BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-02-15 WO disclosed
EP-0920424-A1 NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1999-06-09 EP disclosed
WO-1998007718-A1 NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1998-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160193359-A1 NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF CDK4, CDKL4, FLT4 POLB 4798/4885KDM4E 827/4885MAPT 2019/4885
US-20220160849-A1 CANCER VACCINE FORMULATION CD44, TP53, MUC1 POLB 4789/4885KDM4E 2970/4885MAPT 3086/4885
US-20150231268-A1 HYALURONIC ACID DERIVATIVE HAVING AMINO ACID AND STERYL GROUP INTRODUCED THEREINTO CD44, DAO, FUT6 POLB 4801/4885KDM4E 3563/4885MAPT 4444/4885
US-20130095123-A1 New binder-drug conjugates (ADCs) and use thereof CDK4, CDKL4, FLT4 POLB 4798/4885KDM4E 827/4885MAPT 2019/4885
US-11564971-B2 Hyaluronic acid derivative having amino acid and steryl group introduced thereinto CD44, DAO, FUT6 POLB 4801/4885KDM4E 3563/4885MAPT 4444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.